Comparision of Dual PI-3K/mTOR Inhibitors with mTOR Inhibitors Using a Pre-Clinical Model of Acute Lymphoblastic Leukemia

被引：0
作者：
Wong, Jacky [1 ]
Welschinger, Robert [1 ]
Baraz, Rana [1 ]
Weiss, Jocelyn [1 ]
Bradstock, Ken
Bendall, Linda J.
机构：
[1] Westmead Hosp, Westmead Millenium Inst, Westmead Inst Canc Res, Sydney, NSW, Australia
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1336 / 1336
页数：1
相关论文
共 50 条
[41]   Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib [J].
Maria Serova ;
Armand de Gramont ;
Annemilaï Tijeras-Raballand ;
Célia Dos Santos ;
Maria Eugenia Riveiro ;
Khemaies Slimane ;
Sandrine Faivre ;
Eric Raymond .
Cancer Chemotherapy and Pharmacology, 2013, 71 :1297-1307
[42]   Treatment of Breast Cancer Using Multistage Delivery of PI3K/mTOR Inhibitors [J].
Blanco, E. ;
Sangai, T. ;
Martinez, J. O. ;
Meric-Bernstam, F. ;
Ferrari, M. .
CANCER RESEARCH, 2010, 70
[43]   Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib [J].
Serova, Maria ;
de Gramont, Armand ;
Tijeras-Raballand, Annemilai ;
Dos Santos, Celia ;
Riveiro, Maria Eugenia ;
Slimane, Khemaies ;
Faivre, Sandrine ;
Raymond, Eric .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) :1297-1307
[44]   The PI3K/mTOR Inhibitor NVP-BEZ235 Is a Promising Pre-Clinical Candidate for Therapeutic Intervention in Acute Myeloid Leukemia. [J].
Chapuis, Nicolas ;
Tamburini, Jerome ;
Macone, Alexandre ;
Green, Alexa Samantha ;
Bardet, Valerie ;
Willems, Lise ;
Park, Sophie ;
Ifrah, Norbert ;
Dreyfus, Francois ;
Maira, Sauveur-Michel ;
Mayeux, Patrick ;
Lacombe, Catherine ;
Bouscary, Didier .
BLOOD, 2009, 114 (22) :423-424
[45]   PI3K AND/OR MTOR INHIBITORS: CURRENT STATUS, FUTURE DIRECTIONS [J].
Loi, S. .
ANNALS OF ONCOLOGY, 2012, 23 :59-59
[46]   PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside [J].
Alzahrani, Ali S. .
SEMINARS IN CANCER BIOLOGY, 2019, 59 :125-132
[47]   Synthesis and Biological Activity of Novel PI3K/mTOR Inhibitors [J].
Wang Lei ;
Zheng Guojun ;
Ji Qi ;
Chen Bo ;
Gong Longlong ;
Gao Congmin ;
Du Zhenjian ;
Zhang Xingmin .
CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE, 2017, 38 (09) :1590-1595
[48]   Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma [J].
Westin, Jason R. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05) :335-342
[49]   Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors [J].
Spoerke, Jill ;
O'Brien, Carol ;
Wu, Jenny ;
Desai, Rupal ;
Patel, Rajesh ;
Raja, Rajiv ;
Koeppen, Hartmut ;
Amler, Lukas ;
Hampton, Garret ;
Yan, Yibing ;
Lackner, Mark R. .
CANCER RESEARCH, 2012, 72
[50]   Biomarker evaluation in phase I clinical trials of selective PI3K and PI3k/mTOR inhibitors [J].
Spoerke, Jill ;
Desai, Rupal ;
Patel, Rajesh ;
Fredrickson, Jill ;
Wang, Yulei ;
Levy, Gallia ;
Gendreau, Steve ;
Lauchle, Jennifer ;
Derynck, Mika ;
Raja, Rajiv ;
Koeppen, Hartmut ;
Hampton, Garret ;
Yan, Yibing ;
Lackner, Mark R. .
CANCER RESEARCH, 2013, 73 (08)
12345